

Global Peptide CDMO Pharmaceutical Market Growth (Status and Outlook) 2026-2032

<https://marketpublishers.com/r/G921107DDA3BEN.html>

Date: April 2026

Pages: 143

Price: US\$ 3,660.00 (Single User License)

ID: G921107DDA3BEN

Abstracts

The global Peptide CDMO Pharmaceutical market size is predicted to grow from US\$ million in 2025 to US\$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LPI (LP Information)' newest research report, the 'Peptide CDMO Pharmaceutical Industry Forecast' looks at past sales and reviews total world Peptide CDMO Pharmaceutical sales in 2025, providing a comprehensive analysis by region and market sector of projected Peptide CDMO Pharmaceutical sales for 2026 through 2032. With Peptide CDMO Pharmaceutical sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Peptide

CDMO Pharmaceutical industry.

This Insight Report provides a comprehensive analysis of the global Peptide CDMO Pharmaceutical landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Peptide CDMO Pharmaceutical portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Peptide CDMO Pharmaceutical market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Peptide CDMO Pharmaceutical and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Peptide CDMO Pharmaceutical.

This report presents a comprehensive overview, market shares, and growth opportunities of Peptide CDMO Pharmaceutical market by product type, application, key players and key regions and countries.

Segmentation by Type:

Liquid-phase Peptide Synthesis?LPPS?

Solid-phase Peptide Synthesis?SPPS?

Mixed Phase

Segmentation by Application:

Peptide Supplements

Peptide Vaccines

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Ambiopharm

Auspep

Bachem

Bcn Peptide

Cpc Scientific

Creative Peptides

Chinese Peptide

Csbio

Corden Pharma

Polypeptide

Hybio Pharmaceutical

Peptide Institute

Pepscan

Almac

Vivitide

Creosalus Inc

Scinopharm

Senn Chemicals

Belyntic

Ferring Pharma

Numaferm

Hybio Pharmaceutical

Provepharm Life Solutions

Enzene Biosciences

Piramal Pharma

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Peptide CDMO Pharmaceutical Market Size (2021-2032)
 - 2.1.2 Peptide CDMO Pharmaceutical Market Size CAGR by Region (2021 VS 2025 VS 2032)
 - 2.1.3 World Current & Future Analysis for Peptide CDMO Pharmaceutical by Country/Region (2021, 2025 & 2032)
- 2.2 Peptide CDMO Pharmaceutical Segment by Type
 - 2.2.1 Liquid-phase Peptide Synthesis?LPPS?
 - 2.2.2 Solid-phase Peptide Synthesis?SPPS?
 - 2.2.3 Mixed Phase
 - 2.2.4 Peptide CDMO Pharmaceutical Market Size by Type
 - 2.2.4.1 Peptide CDMO Pharmaceutical Market Size CAGR by Type (2021 VS 2025 VS 2032)
 - 2.2.4.2 Global Peptide CDMO Pharmaceutical Market Size Market Share by Type (2021-2026)
- 2.3 Peptide CDMO Pharmaceutical Segment by Application
 - 2.3.1 Peptide Supplements
 - 2.3.2 Peptide Vaccines
 - 2.3.3 Others
 - 2.3.4 Peptide CDMO Pharmaceutical Market Size by Application
 - 2.3.4.1 Peptide CDMO Pharmaceutical Market Size CAGR by Application (2021 VS 2025 VS 2032)
 - 2.3.4.2 Global Peptide CDMO Pharmaceutical Market Size Market Share by Application (2021-2026)

3 PEPTIDE CDMO PHARMACEUTICAL MARKET SIZE BY PLAYER

3.1 Peptide CDMO Pharmaceutical Market Size Market Share by Player

3.1.1 Global Peptide CDMO Pharmaceutical Revenue by Player (2021-2026)

3.1.2 Global Peptide CDMO Pharmaceutical Revenue Market Share by Player (2021-2026)

3.2 Global Peptide CDMO Pharmaceutical Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 PEPTIDE CDMO PHARMACEUTICAL BY REGION

4.1 Peptide CDMO Pharmaceutical Market Size by Region (2021-2026)

4.2 Global Peptide CDMO Pharmaceutical Annual Revenue by Country/Region (2021-2026)

4.3 Americas Peptide CDMO Pharmaceutical Market Size Growth (2021-2026)

4.4 APAC Peptide CDMO Pharmaceutical Market Size Growth (2021-2026)

4.5 Europe Peptide CDMO Pharmaceutical Market Size Growth (2021-2026)

4.6 Middle East & Africa Peptide CDMO Pharmaceutical Market Size Growth (2021-2026)

5 AMERICAS

5.1 Americas Peptide CDMO Pharmaceutical Market Size by Country (2021-2026)

5.2 Americas Peptide CDMO Pharmaceutical Market Size by Type (2021-2026)

5.3 Americas Peptide CDMO Pharmaceutical Market Size by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Peptide CDMO Pharmaceutical Market Size by Region (2021-2026)

- 6.2 APAC Peptide CDMO Pharmaceutical Market Size by Type (2021-2026)
- 6.3 APAC Peptide CDMO Pharmaceutical Market Size by Application (2021-2026)
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia

7 EUROPE

- 7.1 Europe Peptide CDMO Pharmaceutical Market Size by Country (2021-2026)
- 7.2 Europe Peptide CDMO Pharmaceutical Market Size by Type (2021-2026)
- 7.3 Europe Peptide CDMO Pharmaceutical Market Size by Application (2021-2026)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Peptide CDMO Pharmaceutical by Region (2021-2026)
- 8.2 Middle East & Africa Peptide CDMO Pharmaceutical Market Size by Type (2021-2026)
- 8.3 Middle East & Africa Peptide CDMO Pharmaceutical Market Size by Application (2021-2026)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 GLOBAL PEPTIDE CDMO PHARMACEUTICAL MARKET FORECAST

10.1 Global Peptide CDMO Pharmaceutical Forecast by Region (2027-2032)

10.1.1 Global Peptide CDMO Pharmaceutical Forecast by Region (2027-2032)

10.1.2 Americas Peptide CDMO Pharmaceutical Forecast

10.1.3 APAC Peptide CDMO Pharmaceutical Forecast

10.1.4 Europe Peptide CDMO Pharmaceutical Forecast

10.1.5 Middle East & Africa Peptide CDMO Pharmaceutical Forecast

10.2 Americas Peptide CDMO Pharmaceutical Forecast by Country (2027-2032)

10.2.1 United States Market Peptide CDMO Pharmaceutical Forecast

10.2.2 Canada Market Peptide CDMO Pharmaceutical Forecast

10.2.3 Mexico Market Peptide CDMO Pharmaceutical Forecast

10.2.4 Brazil Market Peptide CDMO Pharmaceutical Forecast

10.3 APAC Peptide CDMO Pharmaceutical Forecast by Region (2027-2032)

10.3.1 China Peptide CDMO Pharmaceutical Market Forecast

10.3.2 Japan Market Peptide CDMO Pharmaceutical Forecast

10.3.3 Korea Market Peptide CDMO Pharmaceutical Forecast

10.3.4 Southeast Asia Market Peptide CDMO Pharmaceutical Forecast

10.3.5 India Market Peptide CDMO Pharmaceutical Forecast

10.3.6 Australia Market Peptide CDMO Pharmaceutical Forecast

10.4 Europe Peptide CDMO Pharmaceutical Forecast by Country (2027-2032)

10.4.1 Germany Market Peptide CDMO Pharmaceutical Forecast

10.4.2 France Market Peptide CDMO Pharmaceutical Forecast

10.4.3 UK Market Peptide CDMO Pharmaceutical Forecast

10.4.4 Italy Market Peptide CDMO Pharmaceutical Forecast

10.4.5 Russia Market Peptide CDMO Pharmaceutical Forecast

10.5 Middle East & Africa Peptide CDMO Pharmaceutical Forecast by Region (2027-2032)

10.5.1 Egypt Market Peptide CDMO Pharmaceutical Forecast

10.5.2 South Africa Market Peptide CDMO Pharmaceutical Forecast

10.5.3 Israel Market Peptide CDMO Pharmaceutical Forecast

10.5.4 Turkey Market Peptide CDMO Pharmaceutical Forecast

10.6 Global Peptide CDMO Pharmaceutical Forecast by Type (2027-2032)

10.7 Global Peptide CDMO Pharmaceutical Forecast by Application (2027-2032)

10.7.1 GCC Countries Market Peptide CDMO Pharmaceutical Forecast

11 KEY PLAYERS ANALYSIS

11.1 Ambipharm

- 11.1.1 Ambipharm Company Information
- 11.1.2 Ambipharm Peptide CDMO Pharmaceutical Product Offered
- 11.1.3 Ambipharm Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
- 11.1.4 Ambipharm Main Business Overview
- 11.1.5 Ambipharm Latest Developments
- 11.2 Auspep
 - 11.2.1 Auspep Company Information
 - 11.2.2 Auspep Peptide CDMO Pharmaceutical Product Offered
 - 11.2.3 Auspep Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
 - 11.2.4 Auspep Main Business Overview
 - 11.2.5 Auspep Latest Developments
- 11.3 Bachem
 - 11.3.1 Bachem Company Information
 - 11.3.2 Bachem Peptide CDMO Pharmaceutical Product Offered
 - 11.3.3 Bachem Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
 - 11.3.4 Bachem Main Business Overview
 - 11.3.5 Bachem Latest Developments
- 11.4 Bcn Peptide
 - 11.4.1 Bcn Peptide Company Information
 - 11.4.2 Bcn Peptide Peptide CDMO Pharmaceutical Product Offered
 - 11.4.3 Bcn Peptide Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
 - 11.4.4 Bcn Peptide Main Business Overview
 - 11.4.5 Bcn Peptide Latest Developments
- 11.5 Cpc Scientific
 - 11.5.1 Cpc Scientific Company Information
 - 11.5.2 Cpc Scientific Peptide CDMO Pharmaceutical Product Offered
 - 11.5.3 Cpc Scientific Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
 - 11.5.4 Cpc Scientific Main Business Overview
 - 11.5.5 Cpc Scientific Latest Developments
- 11.6 Creative Peptides
 - 11.6.1 Creative Peptides Company Information
 - 11.6.2 Creative Peptides Peptide CDMO Pharmaceutical Product Offered
 - 11.6.3 Creative Peptides Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2021-2026)

- 11.6.4 Creative Peptides Main Business Overview
- 11.6.5 Creative Peptides Latest Developments
- 11.7 Chinese Peptide
 - 11.7.1 Chinese Peptide Company Information
 - 11.7.2 Chinese Peptide Peptide CDMO Pharmaceutical Product Offered
 - 11.7.3 Chinese Peptide Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
 - 11.7.4 Chinese Peptide Main Business Overview
 - 11.7.5 Chinese Peptide Latest Developments
- 11.8 Csbio
 - 11.8.1 Csbio Company Information
 - 11.8.2 Csbio Peptide CDMO Pharmaceutical Product Offered
 - 11.8.3 Csbio Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
 - 11.8.4 Csbio Main Business Overview
 - 11.8.5 Csbio Latest Developments
- 11.9 Corden Pharma
 - 11.9.1 Corden Pharma Company Information
 - 11.9.2 Corden Pharma Peptide CDMO Pharmaceutical Product Offered
 - 11.9.3 Corden Pharma Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
 - 11.9.4 Corden Pharma Main Business Overview
 - 11.9.5 Corden Pharma Latest Developments
- 11.10 Polypeptide
 - 11.10.1 Polypeptide Company Information
 - 11.10.2 Polypeptide Peptide CDMO Pharmaceutical Product Offered
 - 11.10.3 Polypeptide Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
 - 11.10.4 Polypeptide Main Business Overview
 - 11.10.5 Polypeptide Latest Developments
- 11.11 Hybio Pharmaceutical
 - 11.11.1 Hybio Pharmaceutical Company Information
 - 11.11.2 Hybio Pharmaceutical Peptide CDMO Pharmaceutical Product Offered
 - 11.11.3 Hybio Pharmaceutical Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
 - 11.11.4 Hybio Pharmaceutical Main Business Overview
 - 11.11.5 Hybio Pharmaceutical Latest Developments
- 11.12 Peptide Institute
 - 11.12.1 Peptide Institute Company Information

- 11.12.2 Peptide Institute Peptide CDMO Pharmaceutical Product Offered
- 11.12.3 Peptide Institute Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
- 11.12.4 Peptide Institute Main Business Overview
- 11.12.5 Peptide Institute Latest Developments
- 11.13 Pepscan
 - 11.13.1 Pepscan Company Information
 - 11.13.2 Pepscan Peptide CDMO Pharmaceutical Product Offered
 - 11.13.3 Pepscan Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
 - 11.13.4 Pepscan Main Business Overview
 - 11.13.5 Pepscan Latest Developments
- 11.14 Almac
 - 11.14.1 Almac Company Information
 - 11.14.2 Almac Peptide CDMO Pharmaceutical Product Offered
 - 11.14.3 Almac Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
 - 11.14.4 Almac Main Business Overview
 - 11.14.5 Almac Latest Developments
- 11.15 Vivitide
 - 11.15.1 Vivitide Company Information
 - 11.15.2 Vivitide Peptide CDMO Pharmaceutical Product Offered
 - 11.15.3 Vivitide Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
 - 11.15.4 Vivitide Main Business Overview
 - 11.15.5 Vivitide Latest Developments
- 11.16 Creosalus Inc
 - 11.16.1 Creosalus Inc Company Information
 - 11.16.2 Creosalus Inc Peptide CDMO Pharmaceutical Product Offered
 - 11.16.3 Creosalus Inc Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
 - 11.16.4 Creosalus Inc Main Business Overview
 - 11.16.5 Creosalus Inc Latest Developments
- 11.17 Scinopharm
 - 11.17.1 Scinopharm Company Information
 - 11.17.2 Scinopharm Peptide CDMO Pharmaceutical Product Offered
 - 11.17.3 Scinopharm Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
 - 11.17.4 Scinopharm Main Business Overview

- 11.17.5 Scinopharm Latest Developments
- 11.18 Senn Chemicals
 - 11.18.1 Senn Chemicals Company Information
 - 11.18.2 Senn Chemicals Peptide CDMO Pharmaceutical Product Offered
 - 11.18.3 Senn Chemicals Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
 - 11.18.4 Senn Chemicals Main Business Overview
 - 11.18.5 Senn Chemicals Latest Developments
- 11.19 Belyntic
 - 11.19.1 Belyntic Company Information
 - 11.19.2 Belyntic Peptide CDMO Pharmaceutical Product Offered
 - 11.19.3 Belyntic Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
 - 11.19.4 Belyntic Main Business Overview
 - 11.19.5 Belyntic Latest Developments
- 11.20 Ferring Pharma
 - 11.20.1 Ferring Pharma Company Information
 - 11.20.2 Ferring Pharma Peptide CDMO Pharmaceutical Product Offered
 - 11.20.3 Ferring Pharma Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
 - 11.20.4 Ferring Pharma Main Business Overview
 - 11.20.5 Ferring Pharma Latest Developments
- 11.21 Numaferm
 - 11.21.1 Numaferm Company Information
 - 11.21.2 Numaferm Peptide CDMO Pharmaceutical Product Offered
 - 11.21.3 Numaferm Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
 - 11.21.4 Numaferm Main Business Overview
 - 11.21.5 Numaferm Latest Developments
- 11.22 Hybio Pharmaceutical
 - 11.22.1 Hybio Pharmaceutical Company Information
 - 11.22.2 Hybio Pharmaceutical Peptide CDMO Pharmaceutical Product Offered
 - 11.22.3 Hybio Pharmaceutical Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
 - 11.22.4 Hybio Pharmaceutical Main Business Overview
 - 11.22.5 Hybio Pharmaceutical Latest Developments
- 11.23 Provepharm Life Solutions
 - 11.23.1 Provepharm Life Solutions Company Information
 - 11.23.2 Provepharm Life Solutions Peptide CDMO Pharmaceutical Product Offered

11.23.3 Provepharm Life Solutions Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2021-2026)

11.23.4 Provepharm Life Solutions Main Business Overview

11.23.5 Provepharm Life Solutions Latest Developments

11.24 Enzene Biosciences

11.24.1 Enzene Biosciences Company Information

11.24.2 Enzene Biosciences Peptide CDMO Pharmaceutical Product Offered

11.24.3 Enzene Biosciences Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2021-2026)

11.24.4 Enzene Biosciences Main Business Overview

11.24.5 Enzene Biosciences Latest Developments

11.25 Piramal Pharma

11.25.1 Piramal Pharma Company Information

11.25.2 Piramal Pharma Peptide CDMO Pharmaceutical Product Offered

11.25.3 Piramal Pharma Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2021-2026)

11.25.4 Piramal Pharma Main Business Overview

11.25.5 Piramal Pharma Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Peptide CDMO Pharmaceutical Market Size CAGR by Region (2021 VS 2025 VS 2032) & (\$ millions)
- Table 2. Peptide CDMO Pharmaceutical Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)
- Table 3. Major Players of Liquid-phase Peptide Synthesis?LPPS?
- Table 4. Major Players of Solid-phase Peptide Synthesis?SPPS?
- Table 5. Major Players of Mixed Phase
- Table 6. Peptide CDMO Pharmaceutical Market Size CAGR by Type (2021 VS 2025 VS 2032) & (\$ millions)
- Table 7. Global Peptide CDMO Pharmaceutical Market Size by Type (2021-2026) & (\$ millions)
- Table 8. Global Peptide CDMO Pharmaceutical Market Size Market Share by Type (2021-2026)
- Table 9. Peptide CDMO Pharmaceutical Market Size CAGR by Application (2021 VS 2025 VS 2032) & (\$ millions)
- Table 10. Global Peptide CDMO Pharmaceutical Market Size by Application (2021-2026) & (\$ millions)
- Table 11. Global Peptide CDMO Pharmaceutical Market Size Market Share by Application (2021-2026)
- Table 12. Global Peptide CDMO Pharmaceutical Revenue by Player (2021-2026) & (\$ millions)
- Table 13. Global Peptide CDMO Pharmaceutical Revenue Market Share by Player (2021-2026)
- Table 14. Peptide CDMO Pharmaceutical Key Players Head office and Products Offered
- Table 15. Peptide CDMO Pharmaceutical Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
- Table 16. New Products and Potential Entrants
- Table 17. Mergers & Acquisitions, Expansion
- Table 18. Global Peptide CDMO Pharmaceutical Market Size by Region (2021-2026) & (\$ millions)
- Table 19. Global Peptide CDMO Pharmaceutical Market Size Market Share by Region (2021-2026)
- Table 20. Global Peptide CDMO Pharmaceutical Revenue by Country/Region (2021-2026) & (\$ millions)

Table 21. Global Peptide CDMO Pharmaceutical Revenue Market Share by Country/Region (2021-2026)
Table 22. Americas Peptide CDMO Pharmaceutical Market Size by Country (2021-2026) & (\$ millions)
Table 23. Americas Peptide CDMO Pharmaceutical Market Size Market Share by Country (2021-2026)
Table 24. Americas Peptide CDMO Pharmaceutical Market Size by Type (2021-2026) & (\$ millions)
Table 25. Americas Peptide CDMO Pharmaceutical Market Size Market Share by Type (2021-2026)
Table 26. Americas Peptide CDMO Pharmaceutical Market Size by Application (2021-2026) & (\$ millions)
Table 27. Americas Peptide CDMO Pharmaceutical Market Size Market Share by Application (2021-2026)
Table 28. APAC Peptide CDMO Pharmaceutical Market Size by Region (2021-2026) & (\$ millions)
Table 29. APAC Peptide CDMO Pharmaceutical Market Size Market Share by Region (2021-2026)
Table 30. APAC Peptide CDMO Pharmaceutical Market Size by Type (2021-2026) & (\$ millions)
Table 31. APAC Peptide CDMO Pharmaceutical Market Size by Application (2021-2026) & (\$ millions)
Table 32. Europe Peptide CDMO Pharmaceutical Market Size by Country (2021-2026) & (\$ millions)
Table 33. Europe Peptide CDMO Pharmaceutical Market Size Market Share by Country (2021-2026)
Table 34. Europe Peptide CDMO Pharmaceutical Market Size by Type (2021-2026) & (\$ millions)
Table 35. Europe Peptide CDMO Pharmaceutical Market Size by Application (2021-2026) & (\$ millions)
Table 36. Middle East & Africa Peptide CDMO Pharmaceutical Market Size by Region (2021-2026) & (\$ millions)
Table 37. Middle East & Africa Peptide CDMO Pharmaceutical Market Size by Type (2021-2026) & (\$ millions)
Table 38. Middle East & Africa Peptide CDMO Pharmaceutical Market Size by Application (2021-2026) & (\$ millions)
Table 39. Key Market Drivers & Growth Opportunities of Peptide CDMO Pharmaceutical
Table 40. Key Market Challenges & Risks of Peptide CDMO Pharmaceutical
Table 41. Key Industry Trends of Peptide CDMO Pharmaceutical

Table 42. Global Peptide CDMO Pharmaceutical Market Size Forecast by Region (2027-2032) & (\$ millions)

Table 43. Global Peptide CDMO Pharmaceutical Market Size Market Share Forecast by Region (2027-2032)

Table 44. Global Peptide CDMO Pharmaceutical Market Size Forecast by Type (2027-2032) & (\$ millions)

Table 45. Global Peptide CDMO Pharmaceutical Market Size Forecast by Application (2027-2032) & (\$ millions)

Table 46. Ambipharm Details, Company Type, Peptide CDMO Pharmaceutical Area Served and Its Competitors

Table 47. Ambipharm Peptide CDMO Pharmaceutical Product Offered

Table 48. Ambipharm Peptide CDMO Pharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 49. Ambipharm Main Business

Table 50. Ambipharm Latest Developments

Table 51. Auspep Details, Company Type, Peptide CDMO Pharmaceutical Area Served and Its Competitors

Table 52. Auspep Peptide CDMO Pharmaceutical Product Offered

Table 53. Auspep Peptide CDMO Pharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 54. Auspep Main Business

Table 55. Auspep Latest Developments

Table 56. Bachem Details, Company Type, Peptide CDMO Pharmaceutical Area Served and Its Competitors

Table 57. Bachem Peptide CDMO Pharmaceutical Product Offered

Table 58. Bachem Peptide CDMO Pharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 59. Bachem Main Business

Table 60. Bachem Latest Developments

Table 61. Bcn Peptide Details, Company Type, Peptide CDMO Pharmaceutical Area Served and Its Competitors

Table 62. Bcn Peptide Peptide CDMO Pharmaceutical Product Offered

Table 63. Bcn Peptide Peptide CDMO Pharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 64. Bcn Peptide Main Business

Table 65. Bcn Peptide Latest Developments

Table 66. Cpc Scientific Details, Company Type, Peptide CDMO Pharmaceutical Area Served and Its Competitors

Table 67. Cpc Scientific Peptide CDMO Pharmaceutical Product Offered

Table 68. Cpc Scientific Peptide CDMO Pharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 69. Cpc Scientific Main Business

Table 70. Cpc Scientific Latest Developments

Table 71. Creative Peptides Details, Company Type, Peptide CDMO Pharmaceutical Area Served and Its Competitors

Table 72. Creative Peptides Peptide CDMO Pharmaceutical Product Offered

Table 73. Creative Peptides Peptide CDMO Pharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 74. Creative Peptides Main Business

Table 75. Creative Peptides Latest Developments

Table 76. Chinese Peptide Details, Company Type, Peptide CDMO Pharmaceutical Area Served and Its Competitors

Table 77. Chinese Peptide Peptide CDMO Pharmaceutical Product Offered

Table 78. Chinese Peptide Peptide CDMO Pharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 79. Chinese Peptide Main Business

Table 80. Chinese Peptide Latest Developments

Table 81. Csbio Details, Company Type, Peptide CDMO Pharmaceutical Area Served and Its Competitors

Table 82. Csbio Peptide CDMO Pharmaceutical Product Offered

Table 83. Csbio Peptide CDMO Pharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 84. Csbio Main Business

Table 85. Csbio Latest Developments

Table 86. Corden Pharma Details, Company Type, Peptide CDMO Pharmaceutical Area Served and Its Competitors

Table 87. Corden Pharma Peptide CDMO Pharmaceutical Product Offered

Table 88. Corden Pharma Peptide CDMO Pharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 89. Corden Pharma Main Business

Table 90. Corden Pharma Latest Developments

Table 91. Polypeptide Details, Company Type, Peptide CDMO Pharmaceutical Area Served and Its Competitors

Table 92. Polypeptide Peptide CDMO Pharmaceutical Product Offered

Table 93. Polypeptide Peptide CDMO Pharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 94. Polypeptide Main Business

Table 95. Polypeptide Latest Developments

Table 96. Hybio Pharmaceutical Details, Company Type, Peptide CDMO Pharmaceutical Area Served and Its Competitors
Table 97. Hybio Pharmaceutical Peptide CDMO Pharmaceutical Product Offered
Table 98. Hybio Pharmaceutical Peptide CDMO Pharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 99. Hybio Pharmaceutical Main Business
Table 100. Hybio Pharmaceutical Latest Developments
Table 101. Peptide Institute Details, Company Type, Peptide CDMO Pharmaceutical Area Served and Its Competitors
Table 102. Peptide Institute Peptide CDMO Pharmaceutical Product Offered
Table 103. Peptide Institute Peptide CDMO Pharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 104. Peptide Institute Main Business
Table 105. Peptide Institute Latest Developments
Table 106. Pepscan Details, Company Type, Peptide CDMO Pharmaceutical Area Served and Its Competitors
Table 107. Pepscan Peptide CDMO Pharmaceutical Product Offered
Table 108. Pepscan Peptide CDMO Pharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 109. Pepscan Main Business
Table 110. Pepscan Latest Developments
Table 111. Almac Details, Company Type, Peptide CDMO Pharmaceutical Area Served and Its Competitors
Table 112. Almac Peptide CDMO Pharmaceutical Product Offered
Table 113. Almac Peptide CDMO Pharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 114. Almac Main Business
Table 115. Almac Latest Developments
Table 116. Vivitide Details, Company Type, Peptide CDMO Pharmaceutical Area Served and Its Competitors
Table 117. Vivitide Peptide CDMO Pharmaceutical Product Offered
Table 118. Vivitide Peptide CDMO Pharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 119. Vivitide Main Business
Table 120. Vivitide Latest Developments
Table 121. Creosalus Inc Details, Company Type, Peptide CDMO Pharmaceutical Area Served and Its Competitors
Table 122. Creosalus Inc Peptide CDMO Pharmaceutical Product Offered
Table 123. Creosalus Inc Peptide CDMO Pharmaceutical Revenue (\$ million), Gross

Margin and Market Share (2021-2026)

Table 124. Creosalus Inc Main Business

Table 125. Creosalus Inc Latest Developments

Table 126. Scinopharm Details, Company Type, Peptide CDMO Pharmaceutical Area Served and Its Competitors

Table 127. Scinopharm Peptide CDMO Pharmaceutical Product Offered

Table 128. Scinopharm Peptide CDMO Pharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 129. Scinopharm Main Business

Table 130. Scinopharm Latest Developments

Table 131. Senn Chemicals Details, Company Type, Peptide CDMO Pharmaceutical Area Served and Its Competitors

Table 132. Senn Chemicals Peptide CDMO Pharmaceutical Product Offered

Table 133. Senn Chemicals Peptide CDMO Pharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 134. Senn Chemicals Main Business

Table 135. Senn Chemicals Latest Developments

Table 136. Belyntic Details, Company Type, Peptide CDMO Pharmaceutical Area Served and Its Competitors

Table 137. Belyntic Peptide CDMO Pharmaceutical Product Offered

Table 138. Belyntic Peptide CDMO Pharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 139. Belyntic Main Business

Table 140. Belyntic Latest Developments

Table 141. Ferring Pharma Details, Company Type, Peptide CDMO Pharmaceutical Area Served and Its Competitors

Table 142. Ferring Pharma Peptide CDMO Pharmaceutical Product Offered

Table 143. Ferring Pharma Peptide CDMO Pharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 144. Ferring Pharma Main Business

Table 145. Ferring Pharma Latest Developments

Table 146. Numaferm Details, Company Type, Peptide CDMO Pharmaceutical Area Served and Its Competitors

Table 147. Numaferm Peptide CDMO Pharmaceutical Product Offered

Table 148. Numaferm Peptide CDMO Pharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 149. Numaferm Main Business

Table 150. Numaferm Latest Developments

Table 151. Hybio Pharmaceutical Details, Company Type, Peptide CDMO

Pharmaceutical Area Served and Its Competitors

Table 152. Hybio Pharmaceutical Peptide CDMO Pharmaceutical Product Offered

Table 153. Hybio Pharmaceutical Peptide CDMO Pharmaceutical Revenue (\$ million),
Gross Margin and Market Share (2021-2026)

Table 154. Hybio Pharmaceutical Main Business

Table 155. Hybio Pharmaceutical Latest Developments

Table 156. Provepharm Life Solutions Details, Company Type, Peptide CDMO
Pharmaceutical Area Served and Its Competitors

Table 157. Provepharm Life Solutions Peptide CDMO Pharmaceutical Product Offered

Table 158. Provepharm Life Solutions Peptide CDMO Pharmaceutical Revenue (\$
million), Gross Margin and Market Share (2021-2026)

Table 159. Provepharm Life Solutions Main Business

Table 160. Provepharm Life Solutions Latest Developments

Table 161. Enzene Biosciences Details, Company Type, Peptide CDMO
Pharmaceutical Area Served and Its Competitors

Table 162. Enzene Biosciences Peptide CDMO Pharmaceutical Product Offered

Table 163. Enzene Biosciences Peptide CDMO Pharmaceutical Revenue (\$ million),
Gross Margin and Market Share (2021-2026)

Table 164. Enzene Biosciences Main Business

Table 165. Enzene Biosciences Latest Developments

Table 166. Piramal Pharma Details, Company Type, Peptide CDMO Pharmaceutical
Area Served and Its Competitors

Table 167. Piramal Pharma Peptide CDMO Pharmaceutical Product Offered

Table 168. Piramal Pharma Peptide CDMO Pharmaceutical Revenue (\$ million), Gross
Margin and Market Share (2021-2026)

Table 169. Piramal Pharma Main Business

Table 170. Piramal Pharma Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Peptide CDMO Pharmaceutical Report Years Considered
- Figure 2. Research Objectives
- Figure 3. Research Methodology
- Figure 4. Research Process and Data Source
- Figure 5. Global Peptide CDMO Pharmaceutical Market Size Growth Rate (2021-2032) (\$ millions)
- Figure 6. Peptide CDMO Pharmaceutical Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 7. Peptide CDMO Pharmaceutical Sales Market Share by Country/Region (2025)
- Figure 8. Peptide CDMO Pharmaceutical Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 9. Global Peptide CDMO Pharmaceutical Market Size Market Share by Type in 2025
- Figure 10. Peptide CDMO Pharmaceutical in Peptide Supplements
- Figure 11. Global Peptide CDMO Pharmaceutical Market: Peptide Supplements (2021-2026) & (\$ millions)
- Figure 12. Peptide CDMO Pharmaceutical in Peptide Vaccines
- Figure 13. Global Peptide CDMO Pharmaceutical Market: Peptide Vaccines (2021-2026) & (\$ millions)
- Figure 14. Peptide CDMO Pharmaceutical in Others
- Figure 15. Global Peptide CDMO Pharmaceutical Market: Others (2021-2026) & (\$ millions)
- Figure 16. Global Peptide CDMO Pharmaceutical Market Size Market Share by Application in 2025
- Figure 17. Global Peptide CDMO Pharmaceutical Revenue Market Share by Player in 2025
- Figure 18. Global Peptide CDMO Pharmaceutical Market Size Market Share by Region (2021-2026)
- Figure 19. Americas Peptide CDMO Pharmaceutical Market Size 2021-2026 (\$ millions)
- Figure 20. APAC Peptide CDMO Pharmaceutical Market Size 2021-2026 (\$ millions)
- Figure 21. Europe Peptide CDMO Pharmaceutical Market Size 2021-2026 (\$ millions)
- Figure 22. Middle East & Africa Peptide CDMO Pharmaceutical Market Size 2021-2026 (\$ millions)
- Figure 23. Americas Peptide CDMO Pharmaceutical Value Market Share by Country in 2025

Figure 24. United States Peptide CDMO Pharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 25. Canada Peptide CDMO Pharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 26. Mexico Peptide CDMO Pharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 27. Brazil Peptide CDMO Pharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 28. APAC Peptide CDMO Pharmaceutical Market Size Market Share by Region in 2025

Figure 29. APAC Peptide CDMO Pharmaceutical Market Size Market Share by Type (2021-2026)

Figure 30. APAC Peptide CDMO Pharmaceutical Market Size Market Share by Application (2021-2026)

Figure 31. China Peptide CDMO Pharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 32. Japan Peptide CDMO Pharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 33. South Korea Peptide CDMO Pharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 34. Southeast Asia Peptide CDMO Pharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 35. India Peptide CDMO Pharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 36. Australia Peptide CDMO Pharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 37. Europe Peptide CDMO Pharmaceutical Market Size Market Share by Country in 2025

Figure 38. Europe Peptide CDMO Pharmaceutical Market Size Market Share by Type (2021-2026)

Figure 39. Europe Peptide CDMO Pharmaceutical Market Size Market Share by Application (2021-2026)

Figure 40. Germany Peptide CDMO Pharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 41. France Peptide CDMO Pharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 42. UK Peptide CDMO Pharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 43. Italy Peptide CDMO Pharmaceutical Market Size Growth 2021-2026 (\$

millions)

Figure 44. Russia Peptide CDMO Pharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 45. Middle East & Africa Peptide CDMO Pharmaceutical Market Size Market Share by Region (2021-2026)

Figure 46. Middle East & Africa Peptide CDMO Pharmaceutical Market Size Market Share by Type (2021-2026)

Figure 47. Middle East & Africa Peptide CDMO Pharmaceutical Market Size Market Share by Application (2021-2026)

Figure 48. Egypt Peptide CDMO Pharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 49. South Africa Peptide CDMO Pharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 50. Israel Peptide CDMO Pharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 51. Turkey Peptide CDMO Pharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 52. GCC Countries Peptide CDMO Pharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 53. Americas Peptide CDMO Pharmaceutical Market Size 2027-2032 (\$ millions)

Figure 54. APAC Peptide CDMO Pharmaceutical Market Size 2027-2032 (\$ millions)

Figure 55. Europe Peptide CDMO Pharmaceutical Market Size 2027-2032 (\$ millions)

Figure 56. Middle East & Africa Peptide CDMO Pharmaceutical Market Size 2027-2032 (\$ millions)

Figure 57. United States Peptide CDMO Pharmaceutical Market Size 2027-2032 (\$ millions)

Figure 58. Canada Peptide CDMO Pharmaceutical Market Size 2027-2032 (\$ millions)

Figure 59. Mexico Peptide CDMO Pharmaceutical Market Size 2027-2032 (\$ millions)

Figure 60. Brazil Peptide CDMO Pharmaceutical Market Size 2027-2032 (\$ millions)

Figure 61. China Peptide CDMO Pharmaceutical Market Size 2027-2032 (\$ millions)

Figure 62. Japan Peptide CDMO Pharmaceutical Market Size 2027-2032 (\$ millions)

Figure 63. Korea Peptide CDMO Pharmaceutical Market Size 2027-2032 (\$ millions)

Figure 64. Southeast Asia Peptide CDMO Pharmaceutical Market Size 2027-2032 (\$ millions)

Figure 65. India Peptide CDMO Pharmaceutical Market Size 2027-2032 (\$ millions)

Figure 66. Australia Peptide CDMO Pharmaceutical Market Size 2027-2032 (\$ millions)

Figure 67. Germany Peptide CDMO Pharmaceutical Market Size 2027-2032 (\$ millions)

Figure 68. France Peptide CDMO Pharmaceutical Market Size 2027-2032 (\$ millions)

Figure 69. UK Peptide CDMO Pharmaceutical Market Size 2027-2032 (\$ millions)

Figure 70. Italy Peptide CDMO Pharmaceutical Market Size 2027-2032 (\$ millions)

Figure 71. Russia Peptide CDMO Pharmaceutical Market Size 2027-2032 (\$ millions)

Figure 72. Egypt Peptide CDMO Pharmaceutical Market Size 2027-2032 (\$ millions)

Figure 73. South Africa Peptide CDMO Pharmaceutical Market Size 2027-2032 (\$ millions)

Figure 74. Israel Peptide CDMO Pharmaceutical Market Size 2027-2032 (\$ millions)

Figure 75. Turkey Peptide CDMO Pharmaceutical Market Size 2027-2032 (\$ millions)

Figure 76. Global Peptide CDMO Pharmaceutical Market Size Market Share Forecast by Type (2027-2032)

Figure 77. Global Peptide CDMO Pharmaceutical Market Size Market Share Forecast by Application (2027-2032)

Figure 78. GCC Countries Peptide CDMO Pharmaceutical Market Size 2027-2032 (\$ millions)

I would like to order

Product name: Global Peptide CDMO Pharmaceutical Market Growth (Status and Outlook) 2026-2032

Product link: <https://marketpublishers.com/r/G921107DDA3BEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G921107DDA3BEN.html>